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We previously showed that COL1A1 expression is up-
regulated at the transcriptional level in systemic sclero-
sis (SSc) fibroblasts and that the CCAAT-binding factor
(CBF) is involved in this increased expression. Ectein-
ascidin 743 (ET-743) is a chemotherapeutic agent that
binds with sequence specificity to the minor groove of
DNA and inhibits CBF-mediated transcriptional activa-
tion of numerous genes. Therefore, we examined the
effects of ET-743 on the increased COL1A1 expression in
SSc fibroblasts. The drug caused a potent and dose-de-
pendent inhibition of type I collagen biosynthesis,
which reached 70–90% at 700 pM without affecting cell
viability. The same drug concentration caused 60–80%
reduction in COL1A1 mRNA levels. The stability of the
corresponding transcripts was not affected. In vitro nu-
clear transcription assays demonstrated a 54% down-
regulation of COL1A1 transcription. Transient transfec-
tions with COL1A1 promoter constructs containing the
specific CBF binding sequence into SSc cells previously
treated with 700 pM ET-743 failed to show an effect on
COL1A1 promoter activity. Furthermore, ET-743 did not
affect the binding of CBF or Sp1 transcription factors to
their cognate COL1A1 elements. However, treatment
with 700 pM ET-743 of stably transfected NIH 3T3 cells
expressing a human type II procollagen gene under the
control of the human COL1A1 promoter caused a greater
than 50% reduction in the production of type II procol-
lagen and a similar decrease in the corresponding type
II procollagen transcripts. These results indicate that
ET-743 is a potent inhibitor of COL1A1 transcription.
However, this effect cannot be explained by a direct
effect on CBF binding to the COL1A1 promoter. Al-
though the exact mechanisms responsible for the tran-
scriptional inhibition of COL1A1 by ET-743 are not ap-
parent, our observations suggest that the drug may be
an effective agent to decrease collagen overproduction
in SSc and other fibrotic diseases.
Fibroblast activation and increased extracellular matrix dep-
osition are central to normal processes such as wound healing.
Dysregulated fibrosis, however, is a pathologic process result-
ing in tissue damage and destruction. Scleroderma or systemic
sclerosis (SSc)1 is a connective tissue disease characterized by
excessive collagen deposition and severe fibrosis of the skin and
various internal organs. There are no curative therapeutic
modalities currently available for this disease. Although pro-
gress has been made toward defining molecular and cellular
factors involved in normal tissue repair and in pathologic fi-
brosis, it is still not clear what distinguishes the normal repar-
ative process from the uncontrolled destructive one occurring
in SSc. Identification of such regulatory pathways could allow
the development of effective pharmacological agents for dis-
eases in which abnormal fibrosis is responsible for their
clinical manifestations.
Several studies have focused on the regulation of COL1A1
and COL1A2, the genes encoding the two chains of type I
collagen, due to the central role that the protein plays in the
progressive and uncontrolled fibrotic process of SSc (for re-
views, see Refs. 1–3). We previously demonstrated that expres-
sion of the COL1A1 gene is primarily regulated at the tran-
scriptional level and that its highest promoter activity in both
normal and SSc fibroblasts resides in the proximal promoter
region (4, 5). Numerous important regulatory elements that are
targets for transcription factor binding, including Sp1 and
CCAAT-binding factor (CBF), have been identified in this re-
gion (6, 7). Previous studies showed that purified CBF, also
known as NF-Y and CP1, binds to the proximal inverted
CCAAT box of the murine COL1A1 promoter, causing a potent
transactivation of its transcription (8). We recently demon-
strated that CBF binds the high affinity inverted CCAAT box of
the human COL1A1 promoter and found a marked increase in
CBF binding activity in SSc fibroblasts when compared with
normal cells (9). Also, another study showed that increased
CBF binding to the COL1A1 proximal promoter is involved in
the activation of COL1A1 transcription by mechanical strain in
a process that is dependent on transforming growth factor 
(10). The importance of the CCAAT box in the transcriptional
activity of numerous genes has been well documented. Indeed,
mutations of this motif in the promoters of the mouse COL1A1
and COL1A2 (11) and the human COL1A1 (12) result in a
significant decrease in their transcriptional activity (reviewed
in Ref. 13). The remarkable evolutionary conservation of the
CCAAT box elements and of their flanking regions in the se-
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quence of the COL1A1 promoter from different species includ-
ing chickens, rats, mice, and humans (14) further emphasizes
its importance in the regulation of collagen gene expression.
Thus, selective targeting and inhibition of CBF-mediated acti-
vation of the type I collagen genes could provide a successful
approach to control the process of fibrosis.
Recent studies of ecteinascidin 743 (ET-743) have shown it to
be a selective inhibitor of transcription of several genes and
that CBF is one of its targets (15, 16). ET-743 is a DNA-
alkylating agent extracted from the marine tunicate Ecteinas-
cidia turbinata that has demonstrated potent antineoplastic
activity against various human tumors including ovarian and
colorectal cancers and advanced sarcoma (17). Numerous clin-
ical trials are currently under way, and the mechanism of
antineoplastic action of this unique agent is under intense
investigation. Although the precise mechanisms of ET-743 ac-
tion have not been elucidated completely, it appears that it
interferes with the function of CBF in the transcription of
numerous genes. There is evidence that ET-743 does not di-
rectly block CBF binding to DNA, but instead, it appears to
interfere with the ability of CBF to recruit and associate with
histone acetylases that are typically required for full gene
promoter function. This sequence-specific effect has been dem-
onstrated in genes such as the multidrug resistance gene,
MDR-1, and the gene encoding heat shock protein 70, HSP70
(15, 16).
Our previous studies were aimed at defining the role of CBF
and other transcription factors in type I collagen regulation
under normal conditions and in pathologic fibrosis (9). Here, we
have extended these studies by examining the inhibitory effects
of ET-743 on type I collagen gene expression in SSc, the pro-
totype of fibrotic diseases. Our data show that the drug causes
potent inhibition of type I collagen biosynthesis and that these
effects are largely due to a reduction of COL1A1 transcription.
Our results provide strong support to the notion that such a
gene transcription targeting approach may prove promising for
the treatment of SSc, a currently fatal condition, and of numer-
ous other diseases characterized by pathologic fibrosis.
EXPERIMENTAL PROCEDURES
Culture of Human Dermal Fibroblasts—Dermal fibroblast cell lines
were established from patients with diffuse SSc of recent onset and
rapid progression, as previously reported (4, 5, 9). All patients studied
were followed at the Scleroderma Center of Thomas Jefferson Univer-
sity and fulfilled published criteria for the classification of SSc (18).
Only untreated cases were studied to avoid spurious results caused by
various therapeutic agents. In all cases, the cell lines were obtained
from full thickness skin biopsies surgically excised from the leading
edge of clinically apparent SSc lesions. Control fibroblasts were ob-
tained from age- and sex-matched individuals undergoing surgical pro-
cedures for unrelated purposes. For all studies, only early passage
fibroblasts (10) were employed to avoid possible phenotypic changes
during extended subculture. Cells were routinely maintained in Dul-
becco’s modified Eagle’s medium supplemented with 10% fetal bovine
serum (Invitrogen), 1% vitamins, 2 mM L-glutamine, and antibiotics and
incubated at 37 °C in a 5% CO2 humidified atmosphere. All studies
were performed in parallel with normal and SSc fibroblasts. ET-743
was obtained from Dr. R. Schultz (Drug Synthesis and Chemistry
Branch, NCI, National Institutes of Health, Bethesda, MD) and from
PharmaMar S.A. (Trescantos, Madrid, Spain) and was prepared as a
stock solution (1 mg/ml) in absolute ethanol and stored at 20 °C until
use. For experiments, the stock solution was diluted in double-distilled
sterile H2O to the desired concentrations.
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium Bromide (MTT)
Cell Viability Assays—Cytotoxity of ET-743 for normal and SSc fibro-
blasts was assessed with the MTT TOX-1 kit assay (Sigma) as described
previously (19). This assay measures the ability of mitochondrial dehy-
drogenase enzymes to convert the soluble yellow MTT salt into an
insoluble purple formazan salt. Only live cells are able to carry out this
reaction. Cells were grown to confluence in 6-well plates with Dulbec-
co’s modified Eagle’s medium containing 10% fetal bovine serum and
treated with L-ascorbic acid phosphate magnesium salt n-hydrate
(Waco Biochemical, Osaka, Japan) for 24 h and then incubated with
various concentrations of ET-743 for 24, 48, and 72 h. MTT was added
to each well and incubated for 2 h, the resulting formasan was dissolved
in acidified isopropyl alcohol, and optical densities were determined at
570 nm using a Micro Plate Reader (Molecular Dynamics, Inc., Sunny-
vale, CA). Colorimetric assays were performed in triplicate.
Determination of Type I Collagen Production—Normal and SSc cells
were plated in 6-well dishes, cultured until confluent, and then pre-
treated for 24 h with 40 g/ml L-ascorbic acid phosphate magnesium
salt n-hydrate in order to optimize their level of collagen production.
For dose-response studies, the cells were incubated with ET-743 (70,
140, and 700 pM) in 10% fetal bovine serum for 48 h. Following treat-
ment, the media were changed with fresh media containing the same
concentrations of ET-743, and the cells were cultured for an additional
24 h. The type I collagen present in the media of the cell cultures was
quantified by an enzyme-linked immusorbent assay using an anti-
human type I collagen polyclonal rabbit antibody (Rockland, Gilberts-
ville, PA). A standard curve was established that related the inhibition
of color development to the concentration of added human type I colla-
gen. The concentration of type I collagen in the culture media was
analyzed in duplicate and determined directly from the standard curve,
which was linear between 30 ng/ml and 2 g/ml type I collagen.
Fibroblast Collagen Biosynthesis—Fibroblast collagen biosynthesis
was examined essentially as described previously (20). Briefly, normal
and SSc fibroblasts were plated in 6-well plates, grown to confluence,
and pretreated with L-ascorbic acid as described above. The cells were
incubated with ET-743 for 24 and 48 h, and then the media were
changed and 600 l of serum-free medium containing the same ET-743
concentrations was added. The cultures were labeled with 4 Ci/ml
14C-labeled proline (ICN Biomedical, Costa Mesa, CA). After 3 h, the
media were harvested from each well, and the cells were trypsinized
and counted. Aliquots of media were taken for immunoprecipitation.
The volume of medium for each immunoprecipitation assay was nor-
malized according to the number of cells present in each well. The
medium was incubated with the type I collagen rabbit polyclonal anti-
body for 2 h, and the antigen-antibody complexes were precipitated
overnight with Protein G-agarose (Roche Applied Science). The precip-
itates were resuspended in 2 SDS sample buffer containing -mer-
captoethanol and boiled for 5 min. Samples were electrophoresed in 6%
polyacrylamide gels, and the radioactive bands were visualized employ-
ing a Storm PhosphorImager and analyzed with ImageQuant version
5.1 software (Amersham Biosciences).
Northern Hybridizations—Fibroblasts were grown to confluence in
100-mm dishes and treated with ET-743 under the same conditions as
those used for the protein experiments. Total RNA was isolated by an
Rneasy Mini Kit (Qiagen, Valencia, CA), and aliquots (6 g/well) were
electrophoresed on formaldehyde 1% agarose gels. The RNA was then
transferred to Hybond™ N filters (Amersham Biosciences) and hy-
bridized to 32P-radiolabeled human cDNA for COL1A1, COL2A1, and
GAPDH. The filters were analyzed using densitometry equipment and
software (ImageQuant version 5.1 software; Amersham Biosciences).
The hybridization signals were normalized to those of GAPDH.
Assessment of Steady-state mRNA Levels and mRNA Stability—
Confluent SSc fibroblasts were incubated for 24 h with or without
ET-743 (700 pM), and mRNA synthesis was inhibited by the addition of
1 g/ml amanitin as described previously (21). Cells were harvested
every 6 h following the addition of amanitin, and total RNA was
isolated and analyzed by Northern hybridizations using specific cDNA
probes for COL1A1 and GAPDH. All data were normalized for the levels
of GAPDH mRNA.
In Vitro Nuclear Transcription Assay—The transcription rates of
COL1A1 were measured by an in vitro nuclear run-off assay. Confluent
SSc fibroblasts were cultured in T-175 flasks in the presence or absence
of 700 pM ET-743 for 48 h. At the end of the incubation, cells were
trypsinized, nuclei were isolated, and transcription reactions were car-
ried out as described previously (21). The nuclei were labeled with 125
Ci of [-32P]UTP (3000 Ci/mmol), and samples were extracted follow-
ing the sequential addition of 2.0 M sodium acetate (pH 4.0), phenol, and
chloroform/isoamyl alcohol-saturated H2O and then precipitated with
isopropyl alcohol. The RNA pellets were dissolved in 50 l of STE buffer
(20 mM Tris-HCl, pH 7.5, 10 mM EDTA, 100 mM NaCl) and passed
through a Probe-Quant G-50 microspin column (Amersham Bio-
sciences). One set of plasmids (10 g each) was prepared for each
experimental condition and dotted onto a nitrocellulose membrane us-
ing a Schleicher & Schuell dot blot minifold. Hybridization and washing
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conditions were carried out as previously described (21). The mem-
branes were exposed for 72 h in a phosphor imaging cassette and
analyzed with phosphor imaging equipment.
Transient Transfections of Human Dermal Fibroblasts—Cells were
transfected employing the FuGene 6 kit (Roche Applied Science) as
described previously (9). Control and SSc fibroblasts were plated and
cultured to 85% confluence in 60-mm dishes and then transfected with
2.0 g of the 804 bp, 675 bp, 174 bp, or 84 bp COL1A1 CAT
constructs described previously (6) or with an SV40 CAT construct.
Transfection experiments were in triplicate and were repeated at least
twice, employing two different SSc fibroblast cell lines. Following 6 h of
incubation, fresh medium containing 700 pM ET-743 was added. The
cells were harvested 48 h after transfection and treated with a lysis
buffer (Roche Applied Science). The protein concentration of the ex-
tracts was determined using the BCA protein assay kit (Pierce). The cell
lysates were assayed for CAT protein employing a CAT enzyme-linked
immusorbent assay kit (Roche Applied Science). CAT activity was de-
termined in cell extracts in triplicate experiments in at least two dif-
ferent cell lines. The concentration of CAT in supernatants was deter-
mined directly from the standard curve of CAT protein.
Electrophoretic Gel Mobility Shift Assay—Confluent cultures of nor-
mal and SSc fibroblasts from three 175-mm flasks were washed with
PBS, and nuclear extracts were prepared as described previously (22).
Electrophoretic gel mobility shift assays using nuclear extracts were
performed as described previously (6, 9, 19). The protein concentration
of the extracts was determined using the Coomassie Plus protein assay
kit (Pierce). Radioactive probes were generated by phosphorylating the
5-ends with polynucleotide kinase (Roche Applied Science) and
[-32P]ATP (ICN, Costa Mesa, CA). Binding reactions containing 10 g
of nuclear extracts, 4 g of poly(dI-dC), and 5–8  104 cpm (0.2 ng) of
radiolabeled probes were incubated for 15 min at room temperature in
a buffer containing 40 mM KCl, 15 mM HEPES, pH 7.9, 1 mM EDTA, 0.5
mM dithiothreitol, 1 mM MgCl2, and 5% glycerol in a total volume of 25
l. To determine the in vitro effects of ET-743 on CBF and Sp1 binding
to their corresponding binding sites in the COL1A1 promoter, the
probes were incubated with either 700 pM or 3 nM of the drug for 10 min,
and then nuclear extracts were added to the mixture for an additional
15 min. To test the specificity of transcription factor binding to the DNA
probes, competition experiments using a 150-fold molar excess of wild
type (WT) or mutated (MT) oligonucleotides were performed. Oligonu-
cleotides containing consensus WT sequences for Sp1 and CBF and
FIG. 1. Effects of ET-743 on normal and SSc fibroblast viability
and morphology. Cytotoxicity of ET-743 was tested by a MTT-based
cytotoxicity assay as described under “Experimental Procedures.” A,
values shown represent the percentage of viable cells following 24, 48,
or 72 h of treatment with a given drug concentration compared with
untreated cells. The results are shown as means  S.E. of three inde-
pendent experiments. Open bars, control; dotted bars, 70 pM ET-743;
horizontally striped bars, 140 pM ET-743; criss-crossed bars, 700 pM
ET-743; hatched bars, 3 nM ET-743. B, photomicrograph of cultured
fibroblasts; , untreated cells; , cells treated with 700 pM ET-743
for 72 h.
FIG. 2. Effects of ET-743 on normal and SSc fibroblast collagen
production. Confluent cultures of four SSc (S1–S4) and two normal
fibroblast (N1 and N2) cell lines were treated under control conditions
or with 70, 140, or 700 pM ET-743 for 48 h. Collagen type I production
was examined by an indirect enzyme-linked immusorbent assay as
described under “Experimental Procedures.” The values represent the
percentage of collagen in the culture media following treatment with
ET-743 compared with untreated cells. The results shown are the
means  S.E. from three separate experiments. Open bars, control;
hatched bars, 70 pM; dotted bars, 140 pM; criss-crossed bars, 700 pM.
FIG. 3. Effect of ET-743 on collagen biosynthesis. Confluent fi-
broblast cultures were incubated under control conditions or with var-
ious drug concentrations (from 0 to 3000 pM) for 24 and 48 h and were
then labeled with [14C]proline for 3 h as described under “Experimental
Procedures.” Following labeling, the culture media were harvested, and
the radiolabeled procollagen in the media representing newly synthe-
sized protein was immunoprecipitated with a specific anti-type I colla-
gen antibody. Aliquots of the media corresponding to equal numbers of
cells were employed for immunoprecipitation. The immunoprecipitates
were solubilized in SDS sample buffer, and equal volumes were elec-
trophoresed in SDS-polyacrylamide gels. The bands corresponding to
radiolabeled procollagen chains were visualized by fluorography and
quantitated. A, representative experiment from one SSc cell line (S2). B
and C representative results from an additional SSc cell line (S1) and a
normal cell line (N1). The migration of pro1(I) and pro2(I) chains
is shown.
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their mutated forms were purchased from Santa Cruz Biotechnology,
Inc. (Santa Cruz, CA). The COL1A1 promoter-specific WT oligonucleo-
tides employed were as follows: oligonucleotide 9/10 (CTCCCAAATT-
GGGGGCCGGGCCAG) containing the Sp1 site and oligonucleotide
13/14 (CAGCTCTGATTGGCTGGGGCA) containing the proximal
CCAAT box. Their mutated forms were as follows: oligonucleotide 9/10
M (CTCCCAAATTGGGTTTCGGGCCAG) containing a mutation in
the Sp1 site and oligonucleotide 13/14 M (CAGCTCTGATCAACT-
GGGGCA) containing a mutation in the CAAT box. These oligonucleo-
tides were obtained from the Nucleic Acid Facility at Thomas Jefferson
University (Philadelphia, PA). DNA-protein complexes were electro-
phoresed through 5% nondenaturing polyacrylamide gels using low
ionic strength buffers. The gels were dried under vacuum and exposed
to x-ray film (Eastman Kodak Co.) at70 °C using intensifying screens.
Treatment of Stably Transfected NIH 3T3 Cells with ET-743—Stably
transfected NIH 3T3 cells expressing the human type II procollagen
gene (COL2A1) under the control of the COL1A1 promoter were em-
ployed for these studies. The establishment of these stable transfec-
tants was described by Ala-Kokko et al. (26). The cells express a
COL1A1/COL2A1 hybrid gene construct comprising 560 bp of the
COL1A1 promoter and the first exon (222 bp) and 1218 bp of the first
intron of the gene driving the transcription of a full-length type II
procollagen gene. The cells were grown to confluence and then were
treated with 0.7 nM ET-743 for 48 h under the same conditions as those
used for the protein experiments with human skin fibroblasts. In sep-
arate experiments, it was found that this concentration of ET-743 did
not cause cytotoxicity to the NIH 3T3 cells.
Western Blot Analysis—For Western blot analysis of type II procol-
lagen production by control or ET-743-treated NIH 3T3 stably trans-
fected cell lines, the cell culture medium was removed and precipitated
with 5% polyethylene glycol (27). The precipitates were collected by
centrifugation and resuspended in a buffer containing 0.4 M NaCl, 25
nM EDTA, 0.4% NaN3, 0.1 M Tris-HCl, pH 7.4. Equal aliquots of the
samples were boiled for 5 min in SDS buffer with 1% -mercaptoethanol
and then applied to 6% polyacrylamide gels and electrophoresed as
described previously (19, 20). The separated proteins were transferred
to nitrocellulose membranes, and following transfer, the membranes
were stained with 0.5% Ponceau S to assure equal loading and transfer
of the proteins. The transferred proteins were reacted for 2 h with a
1:500 dilution of SJ 441 antibody, which is a polyclonal rabbit antibody
specific for the COOH-terminal telopeptide of human type II collagen
(28). After incubation with horseradish peroxidase-conjugated anti-
FIG. 4. Effects of ET-743 on COL1A1 mRNA steady-state levels.
Confluent cultures of one SSc cell line (S1) were incubated with the
ET-743 concentrations shown for 48 h, and the COL1A1 mRNA levels
were analyzed by Northern hybridizations as described under “Exper-
imental Procedures.” A, representative Northern hybridization; B, den-
sitometric analysis. The results represent three independent experi-
ments, and values are expressed as mean  S.E. percentage relative to
untreated fibroblasts. Lane 1, control; lane 2, 70 pM; lane 3, 140 pM; lane
4, 700 pM. Confluent fibroblast cultures of two normal (N1 and N2) and
two SSc (S2 and S3) cell lines were incubated for 48 h with or without
700 pM ET-743, and COL1A1 mRNA levels were determined by North-
ern hybridization analysis. C, representative autoradiograph of North-
ern blot. D, densitometric analysis of Northern blots. The results rep-
resent two independent experiments, and values are expressed as a
percentage relative to untreated fibroblasts.
FIG. 5. Effects of ET-743 on the stability of the COL1A1 tran-
scripts. Confluent fibroblasts were incubated in T-175 flasks in Dul-
becco’s modified Eagle’s medium supplemented with 10% fetal calf
serum and L-ascorbic acid (40 g/ml) with or without 700 pM ET-743 for
24 h, and then -amanitin (1 g/ml) was added to arrest further tran-
scription. Cells were harvested at the intervals shown following the
addition of -amanitin, total RNA was isolated, and equal amounts
were analyzed by Northern hybridizations and densitometry as de-
scribed under “Experimental Procedures.” Densitometric analyses are
shown in arbitrary densitometric units, and the results represent two
independent experiments.
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rabbit antibody (Amersham Biosciences), signals were detected using
the ECL Western blot detection system kit (Amersham Biosciences)
according to the manufacturer’s recommended protocol.
Statistical Analysis—Statistical differences between untreated (con-
trol) and treated cells were assessed employing analysis of variance
with the GraphPad Software Prism 2.01. Values of p  0.05 were
considered significant. The unpaired t test was used to determine sta-
tistical significance.
RESULTS
Effects of ET-743 on Normal and SSc Fibroblast Viability
and Morphology—In order to examine cytotoxic effects of ET-
743 on human adult dermal fibroblasts, confluent cultures of
normal and SSc cells were treated with various ET-743 con-
centrations for 24, 48, and 72 h, and cytotoxicity was measured
by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide assay (Fig. 1A). The data demonstrated that at con-
centrations of up to 700 pM, ET-743 did not cause any detect-
able cytotoxic effect following 72 h of continuous treatment.
However, a concentration of 3 nM of ET-743 decreased cell
viability by about 50% during 48 h of culture and by about 90%
during 72 h of culture, but no cytotoxicity was observed during
the first 24 h (Fig. 1A). Cellular morphology of untreated and
treated confluent fibroblast cultures exposed to various ET-743
concentrations showed that cell morphology was not affected by
concentrations up to 700 pM during 72 h of culture (Fig. 1B).
Effect of ET-743 on Collagen I Production and Biosynthesis—
The effects of ET-743 on collagen I expression were examined
in four different cell lines of SSc and two different cell lines of
normal fibroblasts treated for up to 72 h with 70, 140, or 700 pM
ET-743. The results are shown in Fig. 2. ET-743 reduced type
I collagen production in both types of cells in a dose-dependent
manner. At concentrations of 70 and 140 pM, ET-743 collagen
production was reduced by an average of 50 and 65%, respec-
tively, in four SSc cell lines (S1–S4) and by an average of 30 and
40%, respectively, in two normal fibroblast cell lines (N1 and
N2). The higher ET-743 concentration (700 pM) had a more
potent inhibitory effect (70–90%) in both normal and SSc
fibroblasts. The experiments were carried out in triplicate, and
the variation between samples was 5–10%. Biosynthetic stud-
ies in SSc fibroblasts treated with 70, 140, 700, and 3000 pM
ET-743 showed a strong inhibition of production of newly syn-
thesized type I procollagen (Fig. 3A). At a concentration of 700
pM, ET-743 caused an 85% inhibition during a 24-h treatment
(Fig. 3A, lane 4) and greater than 90% inhibition during a 48-h
treatment (Fig. 3A, lane 9). Studies using 700 pM ET-743 were
also performed in other SSc (Fig. 3B) and normal fibroblast
(Fig. 3C) cell lines with similar results.
ET-743 Down-regulation of COL1A1 Steady-state mRNA
Levels—To investigate the effects of ET-743 on COL1A1 mRNA
levels, confluent cultures of one SSc fibroblast cell line (S1)
were treated for 48 h with 70, 140, and 700 pM ET-743. A 75%
reduction of COL1A1 transcripts was observed during 48-h
treatment with 700 pM ET-743 (Fig. 4, A and B), whereas the
control GAPDH mRNA levels were not affected. Two other SSc
fibroblast cell lines (S2 and S3) and two normal fibroblast cell
lines (N1 and N2) were incubated with 700 pM ET-743, and
COL1A1 mRNA was analyzed following 48 h of treatment (Fig.
4, C and D). A 58% reduction of COL1A1 was observed in the
two SSc fibroblast cell lines (Fig. 4C, lanes 7 and 8). Inhibition
of up to 40% was observed for COL1A1 mRNAs in the two
normal fibroblast cell lines (Fig. 4D, lanes 3 and 4). Further
studies showed that ET-743 did not affect the stability of the
COL1A1 mRNA in either normal or SSc dermal fibroblasts
(Fig. 5).
FIG. 6. Effects of ET-743 on in vitro nuclear transcription. Con-
fluent fibroblast cultures of one SSc cell line (S4) were incubated in
T-175 flasks either under control conditions or treated with 700 pM
ET-743. After 48 h, nuclei were isolated and processed for a nuclear
run-off assay as described under “Experimental Procedures.” A, ali-
quots of 32P-labeled RNA containing equal cpm were hybridized to
dot-blotted cDNAs for 1(I) collagen, GAPDH, and control pUC19 plas-
mid and, following hybridization, were analyzed using phosphor storage
technology. B, densitometric analysis showing the percentage of
COL1A1 transcripts in nuclei from treated cells compared with control.
The values are means  S.E. of results obtained in three independent
experiments. The values obtained were corrected for the transcription
of GAPDH following subtraction of the background represented by
pUC19. Open bar, untreated; dotted bar, ET-743-treated.
FIG. 7. Transient transfection of COL1A1 promoter into un-
treated or ET-743-treated SSc fibroblasts. CAT assays were per-
formed with extracts from two SSc cell lines (S2 and S3) that had been
transfected with 2 g of various COL1A1 promoter CAT constructs and
incubated with 700 pM ET-743 for 48 h following transfection as de-
scribed under “Experimental Procedures.” The amount of CAT protein
driven by each of the promoter CAT constructs was assayed by an
enzyme-linked immunosorbent assay. Results from an illustrative ex-
periment are shown. The values represent the means  S.E. of tripli-
cate wells from representative experiment. At least three experiments
were done, and the values are expressed as concentrations of
CAT enzyme.
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ET-743 Causes a Reduction in COL1A1 Transcription
Rates—To determine whether the changes in COL1A1 mRNA
levels resulted from the modulation of the transcription rates of
the corresponding gene, in vitro transcription assays were per-
formed in SSc fibroblasts treated with 700 pM ET-743 (Fig. 6).
Three experiments were performed using nuclei from SSc cells.
The results showed that COL1A1 transcription was down-reg-
ulated by an average of 50%. The level of COL1A1 transcription
inhibition was similar to the level of inhibition of mRNA
steady-state levels found by Northern hybridization (see Fig.
4). The transcription of the control GADPH was not affected by
ET-743 treatment.
COL1A1 Promoter Activity Is Not Affected by ET-743 in
Transient Transfections—Transient transfection experiments
were performed to determine whether the COL1A1 promoter
region that contains the CBF response element was involved in
the transcriptional down-regulation of COL1A1 activity ob-
served in the in vitro nuclear run-off assays. Various COL1A1
promoter constructs were transfected into normal and SSc
fibroblasts, and then the cells were treated with 700 pM ET-
743. When concentrations of the drug shown in the in vitro
transcription experiments to cause inhibition of COL1A1 tran-
scription (700 pM) were employed, the promoter activity of the
COL1A1 constructs spanning 804 to 84 bp was not down-
regulated (Fig. 7).
To determine whether the transcriptional down-regulation of
COL1A1 expression by ET-743 was due to competition of CBF
binding to its cognate elements within COL1A1, the interaction
of ET-743 with gene promoter sequences known to be involved
in the regulation of COL1A1 transcriptional activity was inves-
tigated. Also, the effects of ET-743 on binding of the regulatory
transcription factors Sp1 and CBF to COL1A1 proximal pro-
moter sequences were examined. Nuclear extracts from un-
treated and ET-743 (700 pM)-treated fibroblasts were examined
by an electrophoretic gel mobility shift assay with consensus
oligonucleotides for Sp1 and CBF and with DNA fragments
from the COL1A1 promoter containing Sp1 or CBF binding
sites. As shown in Fig. 8, nuclear extracts from fibroblasts
treated with ET-743 displayed the same level of Sp1 and CBF
binding activity to consensus Sp1 or CBF oligonucleotides as
untreated cells (Fig. 8, A and C). The specificity of the binding
was confirmed by specific displacement and inhibition of bind-
ing employing an excess of unlabeled oligonucleotides. Similar
binding assays with oligonucleotides corresponding to Sp1 and
CBF binding sites from the COL1A1 promoter also failed to
show any differences between untreated and ET-743-treated
cells (data not shown).
A direct interaction of ET-743 with Sp1 or CBF binding sites
preventing or blocking the subsequent binding of the transcrip-
tion factors was then examined. For this purpose, oligonucleo-
tides containing Sp1 and CBF consensus sequences were incu-
bated in vitro with ET-743, and DNA-protein complex
formation was analyzed by an electrophoretic gel mobility shift
assay. As shown in Fig. 8, B and D, ET-743 at a 700 pM
concentration and at 3 nM did not change the pattern of tran-
scription factor binding obtained without the drug. The results
for Sp1 consensus oligonucleotide are shown in Fig. 8B, and
those for CBF are shown in Fig. 8D. Similar results were
obtained with oligonucleotides corresponding to the Sp1 and
CBF sequences from the COL1A1 promoter (data now shown).
FIG. 8. Electrophoretic gel mobility
shift assay of nuclear extracts (NE)
from SSc fibroblasts interacting with
the Sp1 and CBF consensus after ET-
743 treatment. A, lane 1, NE were incu-
bated with an Sp1 probe; lane 2, NE pre-
pared from fibroblasts treated for 48 h
with 700 pM ET-743 incubated with an
Sp1 probe; lanes 3 and 4, competition
with a 150-fold molar excess of either MT
or WT Sp1 oligonucleotides, respectively.
B, Sp1 consensus oligonucleotide was in-
cubated with 0, 0.7, and 3 nM (lanes 3–5 in
duplicate) ET-743 and analyzed by gel
shift with NE from untreated fibroblasts.
Lanes 1 and 2, competition with MT and
WT Sp1 oligonucleotides. C, lane 3, inter-
action of CBF probe with NE from un-
treated cells. Lane 4, interaction of CBF
probe with NE from fibroblasts treated
for 48 h with 700 pM ET-743; lanes 1 and
2, competition with WT and MT CBF oli-
gonucleotides. D, CBF consensus oligonu-
cleotide was incubated with 0, 0.7, and 3
nM (lanes 3–5 in duplicate) ET-743 and
analyzed with NE from untreated fibro-
blasts. Lanes 1 and 2, competition with
MT and WT CBF oligonucleotide.
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COL1A1 Promoter Activity Is Affected by ET-743 in Stably
Transfected NIH 3T3 Cells—Experiments with stably trans-
fected cells were performed to confirm the transcriptional
down-regulation of COL1A1 activity by ET-743 observed in the
in vitro nuclear run-off assays. NIH 3T3 cells stably transfected
with a cosmid containing a chimeric COL1A1/COL2A1 gene,
encompassing a 2-kb SphI/HindIII fragment from the 5-end of
the human COL1A1 gene, which included the promoter region
(560 bp), the first exon (222 bp), and 1218 bp of the first
intron, and a full-length type II procollagen gene were em-
ployed. The stable transfectants were prepared by Ala-Kokko et
al. (26) and express effectively the cartilage-specific type II
procollagen gene under the control of COL1A1 regulatory ele-
ments. Confluent cultures of NIH 3T3 cells expressing type II
procollagen were treated with 0.7 nM ET-743 for 48 h, and
medium proteins were assayed for type II procollagen by West-
ern blot (Fig. 9). Separate experiments indicated that these
conditions did not cause cytotoxic effects on the stable trans-
fectants (data not shown). Collagen II protein production by
these cells displayed a significant decrease (50%) in response
to ET-743 treatment (Fig. 9A, lanes 3 and 5) compared with
control untreated cells (Fig. 9A, lanes 4 and 6). In order to
confirm the data at the transcription level, total RNA was
isolated from treated and untreated cells, and Northern hybrid-
izations with a COL2A1 cDNA were performed (Fig. 9, C and
D). The level of inhibition of COL2A1 mRNA was similar to the
level of inhibition of type II procollagen production found by
Western blot, and both levels of inhibition were close to those of
COL1A1 transcription inhibition observed in the nuclear run-
off assays (Fig. 6).
DISCUSSION
Here, we describe the first demonstration that the antineo-
plastic drug ET-743 is a potent inhibitor of the expression of
COL1A1 in normal human dermal fibroblasts and, more im-
portantly, that the drug also inhibits the exaggerated overex-
pression of this collagen gene in SSc fibroblasts. These effects
were apparent both at the protein (Figs. 2 and 3) and at the
mRNA levels (Fig. 4). Notably, these effects occurred without
affecting the viability and morphology of normal and SSc fibro-
blasts (Fig. 1). We also show that the drug is effective at low
concentrations (70–700 pM), much lower than those required to
exert antineoplastic effects (15, 16). With a run-off assay em-
ploying isolated fibroblast nuclei, we determined that at this
low concentration (700 pM), ET-743 has a direct transcriptional
effect on COL1A1 (Fig. 6).
Previous studies on the mechanisms of the antineoplastic
effects of ET-743 demonstrated that the drug at much higher
concentrations than those employed here (10–50 nM) inhibits
promoter activation of MDR-I and HSP-70 genes (15, 16). It
was also shown that ET-743 at high concentrations (3 nM)
suppressed okadaic acid induction of the JUN B CAAT box
promoter and that CBF and possibly Sp1 were involved in this
process (23). Therefore, we analyzed whether CBF or Sp1 are
involved in the transcriptional inhibition of ET-743 on
COL1A1. We performed gel shift analysis of the interaction of
Sp1 and CBF oligonucleotides to examine the binding activity
of Sp1 and CBF present in fibroblast nuclear extracts from
untreated or ET-743 (700 pM)-treated cells. Nuclear extracts
from treated fibroblasts yielded normal CBF and Sp1 protein
binding activities, since there was not any detectable quanti-
tative or qualitative change in the Sp1 and CBF complexes
detected by an electrophoretic gel mobility shift assay (Fig. 8).
However, it is necessary to mention that these experiments
may be limited by the size or sequence of the oligonucleotides
employed and, according to Hurley et al. (24), by the stability of
ET-743DNA complexes. The stability of these complexes is
governed by DNA target sequences, since under some condi-
tions the drug is not capable of forming optimally stable bonds
with its corresponding recognition sites in the DNA leading to
the formation of unstable products. The same authors in other
work (25) demonstrated that ET-743 can migrate from a non-
favored bonding sequence (5-AGT) to the favored sequence site
(5-AGC) and that the ET-743-AGT adduct is less stable, dis-
plays a higher degree of molecular motion, and produces dif-
FIG. 9. Western and Northern blot analysis of type II collagen
and type II procollagen mRNA levels in stably transfected NIH
3T3 cells expressing the human type II procollagen gene under
the control of the COL1A1 promoter. Cells were treated 48 h with
0.7 nM of ET-743. A, immunoblotting with anti-collagen II antibody of
culture medium. Lane 1, type II collagen as positive control; lane 2,
medium from NIH 3T3 cells that were not transfected as negative
control; lanes 3 and 4, medium from ET-743-treated (lane 3) and un-
treated cells (lane 4) from experiment 1. Lanes 5 and 6, medium from
ET-743-treated (lane 5) and untreated (lane 6) cells from experiment 2.
Equal loading of the gel was confirmed by Ponceau S staining of the
transfer membrane (data not shown). B, densitometric analysis of West-
ern blots shown in arbitrary densitometric units as means  S.E. of
three independent experiments. C, a representative Northern hybrid-
ization of total RNA from ET-743-treated and untreated NIH 3T3 cells
with a type II procollagen cDNA. D, densitometric analysis of Northern
blots shown in arbitrary densitometric units. The results represent the
averages of two independent experiments, which differed from each
other by less than 10%.
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ferent conformational changes in DNA than the more stable
alkylation product ET-743-AGC.
Our studies employing transient transfections of COL1A1
constructs containing CBF and Sp1 binding sites showed that
in the picomolar concentration range ET-743 is unlikely to
target CBF- or Sp1-mediated transcription. Therefore, the
mechanisms responsible for the transcriptional down-regula-
tion of COL1A1 caused by the drug do not appear to be related
to competition or prevention of CBF or Sp1 binding to their
corresponding sites within the collagen gene promoter. Thus,
the putative mechanisms of the drug on COL1A1 transcription
remain elusive but could include interactions of ET-743 with
other DNA sites close to transcription factor binding sites
within COL1A1 or to sites recognized by other transcriptional
factors. Alternatively, the observed effects could be due to
reversible ET-743 alkylation products that, when formed at
this low concentration of the drug, are not stable, and the drug
could then interact with other preferable, more stable, se-
quences. The experiments employing stably transfected NIH
3T3 cells expressing a COL1A1/COL2A1 hybrid gene indicate
that ET-743 exerts a negative effect on COL1A1 transcription
at very low concentrations (0.7 nM) without causing cytotoxic
effects. A comparison of these results with those obtained em-
ploying transient transfections of the human dermal fibro-
blasts suggests that the drug may be more effective within a
more permissive gene context, perhaps due to the formation of
more stable alkylation products than those formed with the
shorter gene sequences employed in the transient transfection
experiments. Alternatively, it is possible that ET-743 might
prevent association of histone acetylases with the gene, thus
precluding its full promoter function. Therefore, our studies
show that ET-743 displays transcriptional inhibition on
COL1A1 at very low concentrations, an effect that cannot be
explained appropriately by a direct CBF-mediated mechanism.
Thus, although the precise mechanism(s) by which ET-743
affects COL1A1 transcription in normal and SSc dermal fibro-
blasts remains to be determined, the results described here
indicate that the drug may represent a novel and potentially
effective therapy for SSc and other fibrotic diseases.
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